Connect with us

Hi, what are you looking for?

Editor's Pick

Chloroquine Boosters Still Dodging Accountability Four Years On: A Revealing Insight

Over the course of the last four years, chloroquine boosters have been ascending the ladder of promising medical interventions, stoking hope while escalating debates in the realm of public health and bioethics. The drug, primarily known as an antimalarial, gained rapid popularity for its potential effectiveness against the global menace, COVID-19. However, amidst its hurried acceptance and extensive usage, the specter of limited accountability stands as an undeniable concern.

The Support For Chloroquine — Theory Or Hype?

Since its introduction as a probable solution to the COVID-19 pandemic, chloroquine, and its close variant hydroxychloroquine, have been extensively propagated by various groups across the globe. This advocacy stems from in-vitro studies and clinical observations suggesting their potential effectiveness against the virus, coupled with their immunomodulatory properties that could help fight the severe inflammatory response associated with the disease.

Contrarily, skeptics consider this widespread enthusiasm premature and potentially harmful. Citing insufficient scientific evidence and ongoing clinical trials, they voice concerns over the alarming side effects that the drug has been associated with in the past. The bolstering of chloroquine, thus, stands in a pool of debate between its potential benefits and the risks it brings with itself — all while the cloud of limited accountability lingers over its usage.

The Question of Accountability

Accountability, in this context, implies the ethical and legal responsibility of the stakeholders — such as pharmaceutical corporations, healthcare organizations, policymakers, and even the media — in the dispensation and promotion of chloroquine usage.

The current scenario, however, depicts a different picture. The high-speed response to a global crisis has led to swift decisions, where the usual checks and balances have been bypassed. In many countries, chloroquine and hydroxychloroquine received emergency use authorizations, bypassing exhaustive clinical trial protocols. While this may have been born out of necessity, it also undeniably reflects a gap in accountability.

The Ethical Dilemma and Legal Ambiguity

The ethical dilemma surrounding chloroquine usage stems from the traditional medical mantra, First, do no harm. Even when benefit-risk calculations justify the use of a medicine, ethical standards require that each patient’s autonomy, benefit, and safety are respected. However, the emergency use of chloroquine, in absence of solid empirical support, might be perceived as placing patients at undue risk.

Legally, the issue is equally murky. The immunity granted

Enter Your Information Below To Receive Latest News, And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Investing

    Getchell Gold Corp, a junior miner exploring gold mining in Nevada, has just initiated trading on the Frankfurt Exchange under the symbol GGA1. Getchell...

    Latest News

    France has announced the release of François Santoni, a French official that had been held by Niger security forces since July 7. The French...

    Stock

    With government issues, i.e. bonds, it is essential to consider the “long term trend” in order to get the most benefit and create wealth...

    Investing

    Exploration results from the latest Bigfoot Drilling Program at the Tatiggaq Project in Canada’s Thelon Basin, Yukon-Northwest Territories region have demonstrated that the uranium...

    Disclaimer: Incomeinvestingsinsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2023 Incomeinvestingsinsider.com